Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Santoni-Rugiu

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Acta Oncologica (Stockholm, Sweden)|October 10, 2023
Clinical outcomes of <i>ALK</i>+ non-small cell lung cancer in DenmarkKarin Holmskov Hansen, Jakob Sidenius Johansen, Edyta Maria Urbanska, et al.
Oncotarget|September 18, 2018
Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsLise Barlebo Ahlborn, Ida Viller Tuxen, Florent Mouliere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I TrialsIda Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, et al.
NPJ Genomic Medicine|July 3, 2019
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancerBirgitte Bertelsen, Ida Viller Tuxen, Christina Westmose Yde, et al.
Cancer Research Communications|December 10, 2025
Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatinPınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang, et al.
BMC Cancer|August 7, 2025
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid TumorsKristian Egebjerg, Iben Spanggaard, Lise Barlebo Ahlborn, et al.
Frontiers in Bioengineering and Biotechnology|April 20, 2026
Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoidsJoana Leitão-Castro, Alexia Melanie Lopresti, Kamilla Westarp Zornhagen, et al.
Molecular Cancer Therapeutics|July 16, 2025
The recycling collagen receptor uPARAP is a unique mediator of stromal drug delivery to carcinoma cellsKirstine S Nørregaard, Ida M E Larsen, Henrik J Jürgensen, et al.
Lung Cancer Management|May 31, 2024
Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosisJon Lykkegaard Andersen, Jakob Sidenius Johansen, Edyta Maria Urbanska, et al.
Cancer Research|April 30, 2011
MMSET is highly expressed and associated with aggressiveness in neuroblastomaHeidi Rye Hudlebusch, Julie Skotte, Eric Santoni-Rugiu, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Acta Oncologica (Stockholm, Sweden)|October 10, 2023
Clinical outcomes of <i>ALK</i>+ non-small cell lung cancer in DenmarkKarin Holmskov Hansen, Jakob Sidenius Johansen, Edyta Maria Urbanska, et al.
Oncotarget|September 18, 2018
Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsLise Barlebo Ahlborn, Ida Viller Tuxen, Florent Mouliere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I TrialsIda Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, et al.
NPJ Genomic Medicine|July 3, 2019
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancerBirgitte Bertelsen, Ida Viller Tuxen, Christina Westmose Yde, et al.
Cancer Research Communications|December 10, 2025
Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatinPınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang, et al.
BMC Cancer|August 7, 2025
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid TumorsKristian Egebjerg, Iben Spanggaard, Lise Barlebo Ahlborn, et al.
Frontiers in Bioengineering and Biotechnology|April 20, 2026
Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoidsJoana Leitão-Castro, Alexia Melanie Lopresti, Kamilla Westarp Zornhagen, et al.
Molecular Cancer Therapeutics|July 16, 2025
The recycling collagen receptor uPARAP is a unique mediator of stromal drug delivery to carcinoma cellsKirstine S Nørregaard, Ida M E Larsen, Henrik J Jürgensen, et al.
Lung Cancer Management|May 31, 2024
Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosisJon Lykkegaard Andersen, Jakob Sidenius Johansen, Edyta Maria Urbanska, et al.
Cancer Research|April 30, 2011
MMSET is highly expressed and associated with aggressiveness in neuroblastomaHeidi Rye Hudlebusch, Julie Skotte, Eric Santoni-Rugiu, et al.
Pageof 10